More than 100 million people in the U.S. purchase things through the internet annually. The sector is one of the fastest growing in the sales and retail industries. And with more people cutting their cable subscriptions and turning to video streaming sites, such as Netflix and Amazon, the Internet will be in demand more than ever. But people aren't just turning to the internet to watch movies -- last year in the U.S., e-retail sales were over $300 billion. Here are some of the best internet retail stocks TheStreet Quant Ratings says you should consider looking at. Number 3 is Vipshop Holdings Limited. With a 'B' rating, the company's strengths can be seen in its revenue growth and solid stock price performance. 2nd is, Priceline Group. This rating is also a 'B.' Priceline thrives in its notable return on equity and expanding profit margins. Number 1 is Expedia. With a 'B+' rating the company flourishes in its revenue growth and notable return on equity. TheStreet Ratings are algorithmic stock picks based on 32 major data points. S&P 500 stocks rated 'buy' yielded a 16-and-a-half-percent return in 2014, beating the S&P 500 Total Return Index by more than 300 basis points. For the full reports on these stocks, you can check out TheStreet.com/QuantRatings.
More from Video
Amid the Selling, Here's the Big Question Now
How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
One Tweet Pulls the Rug Out From Under the Indexes
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
A Technical Look at the New Dow Jones Industrial Average
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
Conagra Brands Looks Tastier After Its Upgrade to Buy
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Biogen Bulls Get a Lift From Quant Upgrade and Strengthening Charts
Breaking down an approach to the long side of this biotech stock.